William Blair has been made aware of fraudulent activity involving individuals impersonating our employees and brand, including through fake websites and messaging apps like WhatsApp and Telegram. If you have any questions or concerns about someone from William Blair contacting you, please reach out to us via our Contact Us form. Please note — William Blair will never initiate contact with you via messaging apps.
In a special economics conference report, William Blair’s Richard de Chazal highlights commentary from the event, which featured more than 250 public and private companies.
Read more
From addressing GenAI adoption barriers to understanding energy consumption implications, the conversation surrounding AI’s next chapter is critical to unlocking its full potential. Discover our findings in our fourth installment of Navigating the AI Boom now.
Read more
William Blair macro analyst Richard de Chazal unpacks the latest on global tariffs, inflation pressures, recession risks, and why smidcap stocks might be poised for a comeback in a shifting economic landscape.
Read more
Ryan Daniels, William Blair's group head of the healthcare technology and services research sector, explores how America’s rapidly growing senior population is reshaping healthcare, technology, and everyday services through the powerful trend of aging in place.
At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.
Learn more about our mission, vision, and values
We are proud of our signature Global Community Partners program, through which employees nominate organizations to receive catalytic financial support and significant volunteerism opportunities every two years.
More about our community partners
William Blair initiated research coverage of Contineum Therapeutics, Inc. (CTNM $3.93), a clinical-stage biotech developing small-molecule therapeutics for high-unmet-need indications in the prevalent neuroinflammation and immunology space.
Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.
Search our job openings
Stay up-to-date with the latest William Blair news and insights
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
